<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20101113005172N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-10-24</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of therapeutic effect of prolotherapy by glucose, corticosteroid and physical therapy in shoulder teddinopathy</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the efficacy of three different methods in the treatment of rotator cuff tendinopathy of shoulder; Dextrose-prolotherapy, Corticosteroid injections and Physical therapy.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>114</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/34512</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: To randomize the arrival of patients in each of the three study groups, a restriced randomization method using the random allocation rule will be done.This randomization method is used to balance the number of people assigned to each of the groups at the end of the sample collection. In this study, taking into account 38 patients for each group, a total of 120 patients will be considered for entry and randomization. In this method, 120 small balls of the same size are considered in three different colors; 30 yellow balls representing prolethropopy, 30 blue balls representing corticosteroids and 30 green balls representing physical therapy. All small balls are placed in a bag and for each patient, a ball is pulled out of the bag, Blinding description: At the begining of the study, all patients in the three groups will be injected in the same place. Post-injection care is the same in all three groups. The only difference is in patients with the "physical therapy" group, which physical therapies will start 1 week after the injection. It is worth noting that patients in any of the three groups are not aware of the content of the injections.
The collecting person as well as the person analyzing the data are not aware of the patient's treatment method.</study_design>
      <phase>3</phase>
      <hc_freetext>Injury or partial tearing of rotator cuff tendons of the shoulder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Prolotherapy by dextrose. In this group, after placing the patient in the sitting position, 8 cc of dextrose solution 12.5% containing 40 mg lidocaine will be injected in the 3 to 5 points around the shoulder joint (adjacent to the supraspinatus and subscapularis tendons, and other points with tenderness Around the joint) with a 25 gauge, 3.5 cm needle. Intervention 2: Intervention group 2: Corticosteroid injection. In this group, after placement of the patient in the sitting position and under ultrasound guide, 8 cc of 0.1% lidocaine solution containing 80 mg of triamcinolone will be injected in the area adjacent to the supraspinatus and subscapularis tendons (Needle gauge 25, cm5) and around the suprascapular nerve (Needle, 9 cm , 23 gauge). Intervention 3: Intervention group 3: Physical therapy. In this group, after placement of the patient in the sitting position and under ultrasound guide, 8 cc of lidocaine solution 1% will be injected in the area adjacent to the supraspinatus and subscapularis tendons (Needle 25 gauge, 5 cm) and around the suprascapular nerve (spinal needle 23 gauge, 9 cm), and after 1 week, the patient will undergo 10 sessions of physical therapy [every other day] with Tense, Ultrasound and Hot Pack modalities.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The individual data of the participants in the research, after being unidentifiable

When:
Start the access period, 6 months after printing the results

To whom:
Academic researchers

Conditions:
To be used in medical researches

Where to obtain:
Saman Asadi
asadisa60@gmail.com

How to obtain:
Official application through academic or research centers

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Saman Asadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pain clinic, Imam Hossein hospital, Shahid Madani Ave., Imam Ali Blvd.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1617763141</zip>
        <telephone>+98 21 7343 3000</telephone>
        <email>asadisa60@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehrdad Taheri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pain clinic, Imam Hossein hospital, Shahid Madani Ave., Imam Ali Blvd.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1617763141</zip>
        <telephone>+98 21 7343 3000</telephone>
        <email>taheri.1352@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Shoulder pain for at least 6 weeks
Rotator cuff tendinopathy has been confirmed by physical examination and imaging methods
Patient between 18-65 years old</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Past history of shoulder surgery
Diabete mellitus
Malignancy
Immune insufficiency disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M67.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unspecified disorder of synovium and tendon</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Prolotherapy by dextrose. In this group, after placing the patient in the sitting position, 8 cc of dextrose solution 12.5% containing 40 mg lidocaine will be injected in the 3 to 5 points around the shoulder joint (adjacent to the supraspinatus and subscapularis tendons, and other points with tenderness Around the joint) with a 25 gauge, 3.5 cm needle.</i_keyword>
      <i_keyword>Intervention group 2: Corticosteroid injection. In this group, after placement of the patient in the sitting position and under ultrasound guide, 8 cc of 0.1% lidocaine solution containing 80 mg of triamcinolone will be injected in the area adjacent to the supraspinatus and subscapularis tendons (Needle gauge 25, cm5) and around the suprascapular nerve (Needle, 9 cm , 23 gauge).</i_keyword>
      <i_keyword>Intervention group 3: Physical therapy. In this group, after placement of the patient in the sitting position and under ultrasound guide, 8 cc of lidocaine solution 1% will be injected in the area adjacent to the supraspinatus and subscapularis tendons (Needle 25 gauge, 5 cm) and around the suprascapular nerve (spinal needle 23 gauge, 9 cm), and after 1 week, the patient will undergo 10 sessions of physical therapy [every other day] with Tense, Ultrasound and Hot Pack modalities.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain scale and disability in patients with injury or partial tearing of rotator cuff tendons of the shoulder. Timepoint: Measure the pain and disability of the shoulder joint at the beginning of the study (before the intervention) and one week, one month and three months after the end of the treatment interventions. Method of measurement: "Numerical Rating Scale" and "Shoulder Pain And Disability Index".</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-10-02</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Shahid Aerabi Ave., Yaman Blvd., Shahid Chamran Blvd. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
